Combination treatment to save the rectum in low rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy drugs (PD-1 antibody and IL-2) with chemotherapy (CapeOX) in people with very low rectal cancer that hasn't spread. The goal is to preserve the rectum by shrinking the tumor, avoiding surgery, and increasing the chance of a complete response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your rectal cancer must be a type called adenocarcinoma, and it must be located very low, within 5 cm (about 2 inches) from the anal verge.
- Your cancer must be at a stage that has not spread to distant organs (stage I-III, specifically cT1-3N1M0 or cT2-3N0M0).
- You should be generally well and active (ECOG score of 0 or 1).
- You must not have received systemic cancer treatment for colorectal cancer before, nor have been treated with PD-1/PD-L1/CTLA-4 antibodies.
- You must not have an active autoimmune disease, HIV/AIDS, interstitial lung disease, or uncontrolled systemic diseases like severe diabetes or high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (tislelizumab) and standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to help shrink or eliminate the tumor so surgery might be less invasive or not needed, allowing you to keep your rectum.
This trial tests if adding an immunotherapy drug (tislelizumab) to standard chemoradiation and chemotherapy helps patients with ultra-low rectal cancer. It is for patients whose cancer has not spread and can be removed with surgery.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.